Back to search results

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

Abroad (travel likely)RecruitingPHASE1

Conditions

Multiple Myeloma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Washington University School of Medicine, St Louis, Missouri, United States

    Contact: Study coordinator (Michael J Slade, M.D., MSCI) · sladem@wustl.edu · 314-454-8304
    Contact: Principal Investigator (Michael J Slade, M.D., MSCI)
    Zachary Crees, M.D. (Sub-investigator)
    Keith Stockerl-Goldstein, M.D. (Sub-investigator)
    Nathan Singh, M.D., M.S. (Sub-investigator)
    Miriam Y Kim, M.D. (Sub-investigator)
    Joanna C Yang, M.D., M.P.H. (Sub-investigator)
    Ravi Vij, M.D. (Sub-investigator)
    Mark Schroeder, M.D. (Sub-investigator)
    Feng Gao, Ph.D. (Sub-investigator)
Study leads

  • Michael J Slade, M.D., MSCI

    Principal Investigator

    Washington University School of Medicine

View source on ClinicalTrials.gov(opens in a new tab)